ML210

ML210 is a selective, covalent small molecule inhibitor of glutathione peroxidase 4 (GPX4), an antioxidative enzyme that plays a key role in regulating ferroptosis—an iron-dependent form of programmed cell death characterized by the accumulation of lipid peroxides. By binding to the selenocysteine residue in GPX4, ML210 inhibits its activity and induces ferroptosis in cancer cells, including those with mutant RAS and drug-resistant or "persister" phenotypes. This mechanism makes it a promising tool for research into overcoming cancer drug resistance and targeting tumor cells that evade other forms of therapy. The compound has demonstrated antitumor activity in preclinical models and is being explored as a potential therapeutic strategy for cancers such as pancreatic cancer[1][2][3][5][6].

Other names

[4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone